Plasmodium vivax (Pv) remains the primary cause of malaria outside Africa, yet no licensed vaccine is available against this pathogen. Here, we evaluate the immunogenicity and protective efficacy of novel vaccines targeting E140, a recently identified multi-stage antigen conserved across Plasmodium species. Lipid nanop...
R. F. Marques, Guilherme Antonio de Souza Silva, Vitor Antunes da Silva et al.· Molecular Therapy: Nucleic A...· 0 citations
It is demonstrated that the amount of PEG-lipid used in the LNP formulation has a significant impact on humoral immune responses to mRNA-LNP vaccines in mice and can impact memory B cell responses.
Emily F. Daley, Máté Vadovics, F. Coirada et al.· Journal of Immunology· 0 citations
The dsRNA-LNP acts as a potent adjuvant for nucleoside-modified mRNA vaccination, inducing a strong immune activation, representing a potent platform for eliciting balanced, durable antiviral immunity.
F. Coirada, Nelson Cortes Oliveira, Emily F. Daley et al.· Journal of Immunology· 0 citations
The V1V2 mRNA-LNP vaccine is highly immunogenic in mice and rhesus macaques, eliciting cross-clade functional antibodies capable of recognizing native Env, and may provide insights relevant to vaccine testing against other pathogens.
Catarina E. Hioe, Xiao-Mei Liu, C. Yengo et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
